Recently, a prospective study demonstrated that LDA/UFH therapy increased the live-birth rates and reduced obstetric complications, such as preterm delivery and preeclampsia, in women with RPL and anti-β2GPI/HLA-DR antibodies (24). Here, APOH is linked to preeclampsia.